Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 09, 2023, titled "Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in Non-Alcoholic Fatty Liver Disease (NAFLD) patients with comorbidities".
Press Release Jun 09 2023
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced the commencement of the Phase IV EVIDENCES-XI trial for Saroglitazar Mg in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and comorbidities. This study is expected to generate significant Real World Evidence to support clinical guidelines for managing NAFLD and NASH. The press release emphasizes the importance of this trial in addressing unmet healthcare needs in these conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jun 08 2023
- Press Release Jun 07 2023
- Press Release May 18 2023
- Press Release May 17 2023
- Press Release May 10 2023
Later from Zydus Lifesciences
- Press Release Jun 10 2023
- Press Release Jun 13 2023
- Press Release Jun 19 2023
- Press Release Jun 28 2023
- Press Release Jul 03 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences